Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs. Founded in 2009, the company is committed to becoming a global headstream of new drugs to bring benefits to patients around the world. Using its proprietary fully human antibody RenMabTM and RenLiteTM mice, Biocytogen has integrated its monoclonal and bispecific antibody development platforms, in vivo drug efficacy screening platforms and strong clinical development ability to streamline the entire drug development process. Biocytogen is undertaking a large-scale initiative to develop antibody drugs for more than 1000 potential druggable targets, known as Project Integrum. With the implementation of Project Integrum, Biocytogen has entered ongoing collaborations with dozens of partners worldwide to produce first-in-class and/or best-in-class antibody drugs to benefit patients. Currently, the company has established a pipeline of 12 core products, with 2 products in phase II multi-regional clinical trials (MRCT) and 2 products in phase I trials. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA, and Heidelberg, Germany.
